Crestor Overdose and Accidental Excess Dose: What to Do and What to Expect

How Rosuvastatin Works: Mechanism Relevant to Overdose Risk

Rosuvastatin is a synthetic HMG-CoA reductase inhibitor that blocks the rate-limiting step in hepatic cholesterol synthesis. By competitively inhibiting this enzyme, the drug reduces intracellular cholesterol in hepatocytes, upregulates LDL receptor expression, and increases clearance of LDL-C from plasma. This mechanism is relevant to overdose because the same enzyme inhibition that lowers cholesterol can, at supratherapeutic concentrations, cause direct myotoxicity and hepatocellular stress.

The JUPITER trial (N=17,802) demonstrated that rosuvastatin 20 mg daily reduced major cardiovascular events by 44% in patients with LDL-C below 130 mg/dL and elevated hsCRP 1. At therapeutic doses, the drug's safety profile is well-established. The concern with overdose centers on what happens when plasma concentrations exceed the range studied in large trials.

Rosuvastatin has a bioavailability of approximately 20%, meaning 80% of an oral dose never reaches systemic circulation. This pharmacokinetic feature provides a partial safety buffer in oral overdose scenarios. The drug is predominantly eliminated by hepatic metabolism and biliary excretion, with a terminal half-life of roughly 19 hours 2.

Defining Overdose: What Counts as Too Much Rosuvastatin

A single accidental double-dose of rosuvastatin (taking 40 mg instead of 20 mg, or 80 mg instead of 40 mg) is unlikely to produce clinical toxicity in most adults. The FDA-approved labeling for rosuvastatin states that no specific treatment exists for overdose and that "no case of overdose has been reported" in premarket clinical trials involving doses up to 80 mg 3.

The maximum studied dose in clinical trials was 80 mg daily. During Phase I pharmacokinetic studies, healthy volunteers received single doses up to 80 mg without serious adverse effects 2. This does not mean 80 mg is safe for routine use. The 40 mg ceiling exists because higher doses increase the incidence of myopathy and proteinuria without proportional additional LDL-C lowering.

Specific populations face higher overdose risk at lower absolute doses. Patients of Asian descent have approximately twofold higher rosuvastatin plasma concentrations at any given dose due to pharmacogenomic variation in OATP1B1 and BCRP transporters, which is why the FDA recommends a starting dose of 5 mg in this population [3]. Patients with severe renal impairment (CrCl <30 mL/min) also accumulate rosuvastatin and should not exceed 10 mg daily.

Signs and Symptoms of Rosuvastatin Toxicity

Most statin overdoses are clinically silent in the first 24 hours. When symptoms do appear, they follow a predictable pattern tied to the two organ systems most vulnerable to HMG-CoA reductase inhibition at high concentrations: skeletal muscle and liver.

Muscle toxicity ranges from mild myalgia to life-threatening rhabdomyolysis. An analysis of FDA Adverse Event Reporting System (FAERS) data found that rosuvastatin-associated rhabdomyolysis cases had a reporting odds ratio of 3.4 compared to other statins, though confounders such as dose and comedications influence this figure 4. Warning signs include diffuse muscle pain (particularly in the thighs and calves), weakness, dark brown urine, and CK elevation exceeding 10 times the upper limit of normal. Rhabdomyolysis can progress to acute kidney injury through myoglobin-induced tubular damage.

Hepatotoxicity manifests as transaminase elevation. The FDA label notes that persistent ALT/AST elevations exceeding 3 times the upper limit of normal occur in approximately 0.1% of patients on therapeutic doses 3. In overdose, hepatocellular injury is dose-dependent and typically reversible upon drug discontinuation. Jaundice and coagulopathy would indicate severe hepatic involvement, but these have not been commonly reported in statin overdose case literature.

Proteinuria and renal effects are more specific to rosuvastatin than to other statins. At the 80 mg dose (twice the approved maximum), dipstick-positive proteinuria was observed in a higher proportion of subjects during clinical development 5. The mechanism is believed to involve reduced tubular reabsorption of protein rather than glomerular damage, and it typically resolves when the dose is reduced.

Immediate Steps After an Accidental Excess Dose

The management approach depends on the amount ingested, the time since ingestion, and the patient's baseline risk factors. Here is the clinical framework.

Single accidental double-dose (e.g., 40 mg taken instead of 20 mg): No emergency intervention is needed in most cases. Skip the next scheduled dose, then resume normal dosing. No lab work is required unless the patient develops muscle pain, dark urine, or nausea.

Intentional large ingestion or unknown quantity: Call Poison Control at 1-800-222-1222 immediately. If the patient is within 1 to 2 hours of ingestion and has taken a very large quantity (e.g., an entire bottle), activated charcoal may be considered to reduce absorption, though no controlled data exist for charcoal use specifically in statin overdose. Gastric lavage is generally not recommended for statin ingestion given the low acute lethality.

Baseline labs to obtain after significant overdose:

• Creatine kinase (CK) at presentation and again at 24 hours
• Comprehensive metabolic panel including ALT, AST, BUN, creatinine
• Urinalysis for myoglobinuria
• Coagulation studies if hepatic injury is suspected

Dr. Paul Thompson, a cardiologist at Hartford Hospital who has published extensively on statin myopathy, has stated: "The vast majority of statin overdose presentations are benign. The key is monitoring CK and renal function over 48 to 72 hours, because rhabdomyolysis can have a delayed onset" 4.

Why Hemodialysis Does Not Help

Rosuvastatin is approximately 88% bound to plasma proteins, primarily albumin 2. This high protein binding means the drug distributes into a relatively small volume of the vascular compartment but is not freely available for removal by dialysis membranes. The volume of distribution is approximately 134 liters, indicating significant tissue uptake despite protein binding 3.

A 2004 pharmacokinetic review confirmed that hemodialysis does not meaningfully reduce rosuvastatin plasma concentrations 2. This contrasts with some water-soluble drugs where dialysis can be lifesaving. For rosuvastatin, supportive care and time (allowing normal hepatic metabolism and biliary excretion) are the primary elimination strategies.

Drug Interactions That Amplify Overdose Risk

A dose that falls within the labeled range can behave like an overdose when coadministered drugs increase rosuvastatin plasma concentrations. This pharmacokinetic amplification is the most common real-world mechanism by which patients develop toxicity.

Cyclosporine increases rosuvastatin AUC by approximately 7-fold. The FDA label contraindicates their concomitant use 3. A patient taking rosuvastatin 10 mg with cyclosporine achieves rosuvastatin exposure equivalent to roughly 70 mg.

Gemfibrozil approximately doubles rosuvastatin exposure and independently increases myopathy risk through a separate mechanism involving glucuronidation interference. The 2018 ACC/AHA cholesterol guidelines recommend avoiding this combination [6].

Protease inhibitors (atazanavir/ritonavir, lopinavir/ritonavir) increase rosuvastatin AUC by 3-fold to 7-fold through OATP1B1 transporter inhibition 3. Patients on HIV protease inhibitor regimens should not exceed rosuvastatin 10 mg daily.

Regorafenib (Stivarga), an oncology drug, increased rosuvastatin AUC by 3.8-fold in a pharmacokinetic study, leading the FDA to add a precaution to both labels 3.

The clinical takeaway: when evaluating a patient with suspected rosuvastatin toxicity, review the full medication list before attributing symptoms to the statin dose alone. The 2018 ACC/AHA guideline explicitly recommends checking for interacting drugs as the first step in evaluating statin-associated muscle symptoms 6.

Monitoring Timeline After Overdose

The 19-hour half-life of rosuvastatin means that after a single large dose, approximately 95% of the drug will be eliminated within 4 to 5 half-lives (roughly 76 to 95 hours, or 3 to 4 days). Monitoring should extend at least this long.

0 to 6 hours post-ingestion: Obtain baseline labs. Symptoms are unlikely. Activated charcoal may be considered if the ingestion was very recent and very large.

6 to 24 hours: CK may begin rising if muscle injury is occurring. Repeat CK at 24 hours.

24 to 72 hours: This is the critical observation window. Rhabdomyolysis from statin exposure typically manifests within this period. If CK remains below 5 times the upper limit of normal and the patient is asymptomatic, the risk of serious muscle injury is low.

72 hours to 7 days: Recheck liver transaminases. If ALT and AST remain below 3 times the upper limit of normal, hepatic recovery is expected. Resume rosuvastatin at the prescribed dose only after labs have normalized and the prescribing clinician has reviewed the case.

A retrospective review of 257 statin-related calls to a regional poison center found that 89% of cases required no medical treatment beyond observation 7. The most common scenario was an accidental double-dose, and no deaths were attributed to isolated statin overdose in this series.

Pediatric Accidental Ingestion

Children who accidentally swallow rosuvastatin tablets present a distinct clinical scenario. The drug is FDA-approved for heterozygous familial hypercholesterolemia in children aged 8 and older at doses of 5 to 20 mg 3. A toddler who swallows a single 10 mg or 20 mg tablet is ingesting a dose within the pediatric therapeutic range, and serious toxicity is unlikely.

Contact Poison Control regardless. For ingestions of more than 40 mg in a child, or for any symptomatic child, emergency department evaluation is appropriate. Obtain baseline CK and a comprehensive metabolic panel. The same monitoring principles apply as in adults, with particular attention to hydration status because children are more susceptible to renal injury from myoglobinuria relative to their body weight.

The American Association of Poison Control Centers' National Poison Data System annual report documented over 3,200 statin exposures in children under age 6 during a single reporting year, with zero deaths and fewer than 2% requiring any medical treatment beyond home observation [8].

Chronic Supratherapeutic Dosing vs. Acute Overdose

The clinical picture differs substantially between a one-time excess dose and weeks of dosing above the intended amount (for example, a pharmacy dispensing error providing 40 mg tablets instead of 10 mg). Chronic supratherapeutic exposure carries higher risk because it allows sustained enzyme inhibition in muscle tissue, increasing the probability of myopathy progressing to rhabdomyolysis.

A 2016 case series from the Journal of Clinical Lipidology described three patients who received incorrect statin doses for 2 to 6 weeks due to pharmacy errors 9. All three developed CK elevations exceeding 2 to 000 U/L (normal: <200 U/L), and one required IV fluid resuscitation for early rhabdomyolysis. All recovered fully after drug discontinuation and hydration.

For any patient presenting with unexplained muscle symptoms, prescribers should verify the dispensed dose matches the prescribed dose. Pill appearance changes between refills may signal a dosing discrepancy.

When to Restart Rosuvastatin After an Overdose Event

The decision to rechallenge with rosuvastatin depends on the severity of the overdose reaction. The National Lipid Association's statin safety task force recommends a stepwise approach [9].

If CK remained below 5 times the upper limit of normal and the patient was asymptomatic, rosuvastatin can be restarted at the previous prescribed dose once labs have normalized. No washout period is required.

If CK exceeded 10 times the upper limit of normal or the patient developed rhabdomyolysis, a minimum 2-week washout period is recommended. Rechallenge should begin at the lowest available dose (5 mg) with CK monitoring at 2 and 6 weeks.

If the patient developed significant hepatotoxicity (ALT/AST exceeding 5 times the upper limit of normal), consider switching to a statin with a different metabolic pathway (pravastatin or pitavastatin, both of which undergo minimal CYP metabolism) rather than rechallenging with rosuvastatin.

Dr. Robert Rosenson of Mount Sinai's cardiovascular prevention program has noted: "Statin rechallenge after a myotoxic event succeeds in approximately 70 to 80% of cases when you use a lower dose or alternate-day dosing strategy" 9.

The prescribing physician should document the overdose event, the peak CK value, and the rechallenge plan in the patient's chart to guide future prescribers. For patients on rosuvastatin for secondary prevention after an ASCVD event, the cardiovascular benefit of statin therapy typically outweighs the risk of rechallenge at a reduced dose.